Loading...
Please wait, while we are loading the content...
Similar Documents
Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study
| Content Provider | MDPI |
|---|---|
| Author | Dardari, Dured Thomas, Claire Laborne, Francois-Xavier Tourte, Caroline Henry, Elodie Erblang, Megan E. Bourdon, Stéphanie Penfornis, Alfred Lopes, Philippe |
| Copyright Year | 2022 |
| Description | The RANKL-GLYC study aims to explore the impact of the rapid correction of chronic hyperglycemia on the receptor activator of nuclear factor-kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG). RANKL and OPG are considered the main factors in the pathophysiology of Charcot neuroarthropathy, a devastating complication of the joints that remains poorly understood. The study began recruiting patients in September 2021 and ends in June 2022; the final study results are scheduled for January 2023. |
| Starting Page | 555 |
| e-ISSN | 16489144 |
| DOI | 10.3390/medicina58040555 |
| Journal | Medicina |
| Issue Number | 4 |
| Volume Number | 58 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2022-04-18 |
| Access Restriction | Open |
| Subject Keyword | Medicina Diabetes Charcot Neuroarthropathy Receptor Activator of Nuclear Factor-kappa B Ligand (rankl) Osteoprotegerin (opg) Hba1c |
| Content Type | Text |
| Resource Type | Article |
